Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in New Orleans, Louisiana, November 7-10, 2025.
Despite having multiple pulmonary arterial hypertension therapies from 3 different pathways used in combination for decades, too many patients still die from the disease, Dr. McLaughlin said. Clinical trials show that adding sotatercept (Winrevair) provides significant benefits even in heavily pretreated patients already on conventional combination therapies.
While intermediate and high-risk patients who haven’t achieved low-risk status clearly need additional therapy, sotatercept should also be considered for low-risk patients who still have significant disease burden or right ventricular dysfunction. The key question for every patient, regardless of risk category, is: “How can we optimize their long-term outcomes?” Sotatercept should be evaluated as a potential option across all risk levels.
Read more at this link on the American Journal of Managed Care
Summary by Deger Kesimoglu, volunteer for the Alliance for Pulmonary Hypertension
Photo credit: American Journal of Managed Care TV